Rickettsial disease IVDs Australia - English - Department of Health (Therapeutic Goods Administration)

rickettsial disease ivds

esl biosciences australia 2012 pty ltd - ct868 - rickettsial disease ivds - ivds that are intended to be used in testing to provide information about infection with or exposure to coxiella

Measles (rubeola) virus IVDs Australia - English - Department of Health (Therapeutic Goods Administration)

measles (rubeola) virus ivds

esl biosciences australia 2012 pty ltd - ct738 - measles (rubeola) virus ivds - ivds for the qualitative and quantitative determination of antibodies to measles virus

Severe acute respiratory syndrome-associated coronavirus IVDs Australia - English - Department of Health (Therapeutic Goods Administration)

severe acute respiratory syndrome-associated coronavirus ivds

esl biosciences australia 2012 pty ltd - ct772 - severe acute respiratory syndrome-associated coronavirus ivds - laboratory test systems (ivd) for the direct detection of severe acute respiratory syndrome-associated coronavirus by real time pcr and laboratory test systems (ivd) for the presence of antibodies to severe acute respiratory syndrome-associated coronavirus in human biological specimens

Parvovirus B19 IVDs Australia - English - Department of Health (Therapeutic Goods Administration)

parvovirus b19 ivds

esl biosciences australia 2012 pty ltd - ct767 - parvovirus b19 ivds - for in vitro diagnostic use in testing to provide information about infection with or exposure to parvovirus including pre-natal screening of women in order to determine their immune status

Varicella zoster virus (Human herpesvirus 3) IVDs Australia - English - Department of Health (Therapeutic Goods Administration)

varicella zoster virus (human herpesvirus 3) ivds

esl biosciences australia 2012 pty ltd - ct756 - varicella zoster virus (human herpesvirus 3) ivds - for in vitro diagnostic use in testing to provide information about infection with or exposure to the varicella zoster virus (vzv)

General laboratoryware IVDs Australia - English - Department of Health (Therapeutic Goods Administration)

general laboratoryware ivds

esl biosciences australia 2012 pty ltd - ct945 - general laboratoryware ivds - general laboratory ware that is used in conjunction with ids-isys systems

Fungal infectious disease IVDs Australia - English - Department of Health (Therapeutic Goods Administration)

fungal infectious disease ivds

esl biosciences australia 2012 pty ltd - ct354 - fungal infectious disease ivds - ivds that are intended to be used in testing to provide information about infection with or exposure to one or a number of yeast and/or fungal diseases.

BIORELEASE DESLORELIN (BRD) Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

biorelease deslorelin (brd)

dechra veterinary products (australia) pty. ltd. - deslorelin as deslorelin acetate - parenteral liquid/solution/suspension - deslorelin as deslorelin acetate ungrouped active 1.25 mg/ml - endocrine system

ZEBINIX eslicarbazepine acetate 800 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

zebinix eslicarbazepine acetate 800 mg tablet blister pack

maxx pharma pty ltd - eslicarbazepine acetate, quantity: 800 mg - tablet, uncoated - excipient ingredients: magnesium stearate; croscarmellose sodium; povidone - zebinix is indicated as:,? monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;,? adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.

ZEBINIX eslicarbazepine acetate 200 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

zebinix eslicarbazepine acetate 200 mg tablet blister pack

maxx pharma pty ltd - eslicarbazepine acetate, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; croscarmellose sodium - zebinix is indicated as:,? monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;,? adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation.